Cell Source, Inc. (CLCS)
Stock Price: $1.16 USD
-0.34 (-22.67%)
Updated May 14, 2021 3:58 PM EDT - Market closed
| Market Cap | 37.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.44M |
| Shares Out | 32.66M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $1.16 |
| Previous Close | $1.50 |
| Change ($) | -0.34 |
| Change (%) | -22.67% |
| Day's Open | 1.50 |
| Day's Range | 1.16 - 1.50 |
| Day's Volume | 2,650 |
| 52-Week Range | 0.65 - 2.55 |
News
There are no news available yet.
About CLCS
Cell Source, Inc., a biotechnology company, develops cell therapy treatments. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, such as treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various canc... [Read more...]
| Industry Biotechnology | Founded 2011 |
| Stock Exchange OTCMKTS | Ticker Symbol CLCS |